

1 **TNF may negatively regulate phagocytosis of Devil Facial Tumor disease**  
2 **cells by activated macrophages**

3 Xinying Li<sup>1,2</sup>, Jocelyn Darby<sup>1,3</sup>, A. Bruce Lyons<sup>3\*</sup> Gregory M. Woods<sup>1,3\*</sup> and Heinrich Körner<sup>1,</sup>  
4 <sup>4\*#</sup>

5 <sup>1</sup>*Menzies Institute for Medical Research, College of Health and Medicine, University of*  
6 *Tasmania, Hobart, Tasmania, Australia*

7 <sup>2</sup>*School of Life Science, Anhui Medical University, Hefei, People's Republic of China*

8 <sup>3</sup>*School of Medicine, College of Health and Medicine, University of Tasmania, Hobart,*  
9 *Tasmania, Australia*

10 <sup>4</sup>*Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-*  
11 *inflammatory and Immunopharmacology, Ministry of Education, Engineering Technology*  
12 *Research Centre of Anti-inflammatory and Immunodrugs in Anhui Province, Hefei, Anhui,*  
13 *People's Republic of China*

14 **\* These authors share Senior Authorship**

15 **# Corresponding author:** Menzies Institute for Medical Research Tasmania, MS2, 17  
16 Liverpool St, Hobart, Tasmania 7000, Australia and Institute of Clinical Pharmacology, Anhui  
17 Medical University, Key Laboratory of Anti-inflammatory and Immunopharmacology,  
18 Ministry of Education, Engineering Technology Research Center of Anti-inflammatory and  
19 Immunodrugs in Anhui Province, Hefei, Anhui, People's Republic of China; Tel.: (+61) 3 6226  
20 4698; Fax: (+61) 3 6226 7704; Email: heinrich.korner@utas.edu.au

21 **Running title: Phagocytosis of tumor cells**

22 **Key words: TNF, phagocytosis, macrophages. Devil Facial Tumor disease. Nitric Oxide**

23 **Abstract**

24 Macrophage phagocytosis of pathogens and tumour cells is an important early event in  
25 protection against infectious disease and cancer. As tumour necrosis factor  $\alpha$  (TNF) is an  
26 important cytokine in macrophage activation, we investigated the involvement of TNF in  
27 macrophage phagocytosis of tumour cells. We used Devil Facial Tumour Disease (DFTD)  
28 cancer cells as the target tumour cells. The Tasmanian devil (*Sarcophilus harrisii*) population  
29 is threatened by the transmissible DFTD. Using DFTD cells provided the opportunity to  
30 determine if these cells can be phagocytosed and investigate requirement for TNF. As effector  
31 cells, bone marrow derived macrophages (BMDMs), generated from C57BL/6 wild type  
32 (B6.WT) and C57BL/6 TNF<sup>-/-</sup> (B6.TNF<sup>-/-</sup>) mice were used. Phagocytosis of DFTD cells was  
33 investigated by confocal microscopy and flow cytometry. DFTD cells were **consistently**  
34 phagocytosed by B6.WT and B6.TNF<sup>-/-</sup> BMDMs with similar efficiency *in vitro*. Consequently  
35 the DFTD cells are not resistant to phagocytosis. Following activation by exposure to IFN $\gamma$  and  
36 LPS or LPS alone, B6.TNF<sup>-/-</sup> BMDMs had higher phagocytic efficiency and lower nitric oxide  
37 (NO) production compared to wild-type controls. **In addition, NO seems to be unlikely to be**  
38 **the involved in phagocytosis efficiency in IFN $\gamma$  and LPS activated B6.TNF<sup>-/-</sup> macrophages and**  
39 **consequences thereof.** Our results indicate that TNF is not required for IFN $\gamma$  and LPS or LPS  
40 alone activation of macrophage phagocytosis. TNF may negatively regulate macrophage  
41 phagocytosis of tumour cells.

42

## 43 **Introduction**

44 Tumour necrosis factor  $\alpha$  (TNF) is a member of the tumour necrosis factor family with two  
45 cognate receptors, TNF receptor 1 (TNFR1) and TNFR2 (Sedgwick et al., 2000). Under steady-  
46 state conditions TNF is synthesised at low levels predominately by T cells and macrophages,  
47 but following challenge macrophages increase the production of TNF dramatically (Mannel et  
48 al., 1980).

49 Macrophages are a heterogeneous population of innate immune cells with important roles in  
50 tissue regeneration and immune defence (Hu et al., 2017). One of their evolutionary oldest  
51 effector functions is phagocytosis, the engulfment of pathogens or cells debris, or more general,  
52 particles followed by an uptake of the engulfed material in specialised vesicles termed phago-  
53 lysosomes (Aderem and Underhill, 1999). This mechanism was originally described over 100  
54 years ago (Tauber, 2003) and involves receptor recognition, cytoskeleton rearrangement and  
55 phagosome maturation (Taylor et al., 2005). During the process of phagocytosis pathogens are  
56 endocytosed and become engulfed as membrane coated phagosomes. The phagosomes then  
57 fuse with lysosome to form an acidic environment to degrade the pathogens (Underhill and  
58 Ozinsky, 2002). Actin polymerization is required for pathogen uptake and reactive oxygen and  
59 nitrogen species contribute to the degradation of the pathogen (Aderem and Underhill, 1999).

60 In response to environmental stimuli, macrophages differentiate into classically activated,  
61 proinflammatory (M1) macrophages or alternatively activated, anti-inflammatory (M2)  
62 macrophages. M1 macrophages require exposure to the pro-inflammatory cytokines interferon  
63 gamma (IFN $\gamma$ ) either alone or in combination with TNF or a Toll like receptor ligand such as  
64 LPS. M2 macrophages require exposure to IL-4 and/or IL-13 (Murray et al., 2014). The  
65 differentiation to either M1 or M2 macrophages is not only driven by cytokines but also  
66 negatively regulated by TNF. The presence of TNF is necessary for macrophages to  
67 differentiate to the M1 type. In absence of TNF a significant proportion of macrophages co-

68 expresses the M2-marker Arginase-1 (Arg1) interfering with the production of NO (Kratochvill  
69 et al., 2015; Schleicher et al., 2016).

70 Interestingly, and in agreement with their different functions, M1 and M2 macrophages display  
71 different levels of phagocytosis (Gordon and Martinez, 2010; Varin et al., 2010). IFN $\gamma$   
72 activation of M1 macrophages enhances phagocytosis of apoptotic cells (Fernandez-  
73 Boyanapalli et al., 2010). In contrast, IL-4 induced M2 macrophages exhibit impaired bacterial  
74 phagocytosis due to reduced phagosome formation (Varin et al., 2010). Specifically, TNF  
75 inhibits macrophage phagocytosis of apoptotic cells in a time and dose dependent manner  
76 (Borges et al., 2009). TNF deficient macrophages have a reduced ability to endocytose  
77 nontypeable *Haemophilus influenza* (Leichtle et al., 2010). However, TNF appears to enhance  
78 IFN $\gamma$  primed macrophage phagocytosis of apoptotic cells in a NO dependent manner  
79 (Fernandez-Boyanapalli et al., 2010). Therefore, the effects of TNF in macrophage  
80 phagocytosis under different activation states of macrophages are unclear. Consequently, we  
81 investigated role of TNF in macrophage phagocytosis of tumour cells under different activation  
82 conditions.

83 The tumour cells used in this study were Devil Facial Tumour Disease (DFTD) cells. The first  
84 case of DFTD was recorded in 1996 and is primarily responsible for the catastrophic decline  
85 of the Tasmanian devil (*Sarcophilus harrisii*) population (Jones et al., 2008). In 2016 a second  
86 and independent DFTD was discovered and has been called DFT2 to distinguish it from the  
87 first DFTD, now identified as DFT1 (Pye et al., 2016b). DFTD is a transmissible cancer  
88 transmitted as an allograft by biting and is characterized by tumours located on face and neck  
89 of diseased devils (Jones et al., 2008). Functional and histological analyses performed to date  
90 indicate that the devil has a competent adaptive immune system (Kreiss et al., 2009). Since it  
91 is practically and ethically problematic to harvest tissues from *S. harrisii* many aspects of the  
92 innate immune system have not yet been explored and mouse models need to be established.

93 For example, it is unknown if DFTD cells can be phagocytosed by mouse macrophages and if  
94 these cells after considering limitations can be used as model.

95 Therefore, we firstly determined if DFTD cells could be phagocytosed then examined the  
96 activation status of macrophages and the effect of TNF on their ability to phagocytose DFTD  
97 cells. We used bone marrow derived macrophages (BMDMs) isolated from wild type and  
98 B6.TNF<sup>-/-</sup> mice and found that TNF inhibits macrophage phagocytosis efficiency following  
99 activation by IFN $\gamma$ /LPS and LPS.

100

## 101 **Materials and Methods**

### 102 **Animals**

103 The gene-targeted C57BL/6 (B6.TNF<sup>-/-</sup>) mouse strains deficient for TNF were generated on a  
104 genetically pure C57BL/6 (B6.WT) background as described (Körner et al., 1997). The  
105 screening procedure followed the protocols described previously (Körner et al., 1997). All  
106 animals were housed in pathogen-free conditions. Mice aged 8-16 weeks were used in all  
107 experiments. The experiments were approved by the Animal Ethics Committee of University  
108 of Tasmania (UTAS) under the ethics number A13934.

### 109 **Cell culture**

110 BMDM from B6.WT and B6.TNF<sup>-/-</sup> mice were generated from pelvic and femoral bones as  
111 described (Schleicher and Bogdan, 2009). BMDM were cultured in RPMI 1640 medium  
112 (Gibco, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, USA),  
113 10% L929-conditioned medium (containing M-CSF), 5% horse serum (Gibco, USA), 1%  
114 penicillin and streptomycin (Gibco, USA), 1% nonessential amino acids (Gibco, USA) and 2-  
115 mercaptotoethanol (Gibco, USA). After culture for 7 days, BMDM were untreated or treated  
116 with the following substances: 20 ng/ml IFN $\gamma$  (Peprotech, USA), 100 ng/ml LPS (Sigma, USA)  
117 or a combination of IFN $\gamma$  and LPS for 24 hours or 5 ng/ml IL-4 (Peprotech, USA) for 48 hours.  
118 The purity of macrophages obtained was always at least 90% by using CD11b (PE-cy7,  
119 eBioscience) and F4/80 (PerCP Cy5.5, Biolegend) in flow cytometry.

120 The Devil Facial Tumour Disease cell line, C5065, was established from primary tumour  
121 samples (Pearse et al., 2012). Cells were grown in RPMI-1640 medium (Gibco, USA)  
122 supplemented with 10% FBS (Bovogen Biological, Australia) and 5mM L-glutamine (Sigma,  
123 USA). DFTD cells were maintained in a humidified 5% CO<sub>2</sub> incubator at 35 °C. Phagocytosis  
124 assays required co-culturing of mouse macrophages with DFTD cells were maintained at 37 °C.

125

**126 Flow cytometry phagocytosis assay and calculations**

127 BMDM (effector cells) were labelled with CellTrace™ Violet (CTV, Invitrogen, USA), DFTD  
128 cells (target cells) were labelled with 5(6)-Carboxyfluorescein diacetate N-succinimidyl ester  
129 (CFSE, Invitrogen, USA) according to manufacturer's instruction. BMDMs were resuspended  
130 in cell culture medium at  $10^6$ /ml. Serial dilution of 100  $\mu$ l BMDMs were performed to obtain  
131 effector to target ratios of 10:1, 5:1 with  $10^4$  target cells. The phagocytosis assays were  
132 performed in duplicate or triplicate and incubated for 4 hours and 24 hours at 37 °C and for 4  
133 hours at 4 °C for the negative control. The plates were analysed on a BD Canto II flow  
134 cytometer and data calculations were performed with Flowjo V10.1 software (Tree star, USA),  
135 and Graphpad Prism 5 for graphic display. To calculate percentage of DFTD cells  
136 phagocytosed, three gates were identified. R1, total CFSE<sup>+</sup> tumour cells = total tumour cells.  
137 R2, CFSE<sup>+</sup>/CTV<sup>+</sup> dual labelled cells = tumour cells phagocytized by macrophages. R3,  
138 CFSE<sup>+</sup>/CTV<sup>-</sup> cells = free tumour cells. The formula used for calculating phagocytosis was as  
139 follows: percentage of phagocytosis= R2/R1 x 100. For the 24 hours incubation (to avoid the  
140 complication of cell division of DFTD cells), the absolute numbers of DFTD cells were  
141 calculated by including all events (i.e. cells) or enumerating with a known number of cell count  
142 beads (eBioscience, USA) added to enable absolute numbers to be determined by ratio. For the  
143 bead count method, 5,000 beads were added to wells before the analysis by flow cytometry.  
144 The number of cells and beads were recorded and the number of DFTD cells not phagocytosed  
145 were calculated according to the ratio of analysed beads to 5,000. The number of DFTD cells  
146 remaining = (5000/number of beads collected) x R3 cells. Spontaneous DFTD cell death during  
147 short term assays was negligible.

148

**149 Cell staining and confocal microscopy for evidence of phagocytosis**

150 CTV labelled BMDMs were grown in 24 well plates on 0.2% gelatine (BD Bioscience, USA)  
151 coated 12 mm coverslips. CFSE labelled DFTD cells were added when the coverslip was  
152 almost confluent with BMDMs. After 4 and 24 hours incubation, cells were gently washed  
153 with PBS. Cells were permeabilized with 0.25% Triton X-100 (Sigma, USA) for 20 min and  
154 blocked with a 1% BSA (Sigma, USA) in PBS solution for 20 min. Antibody staining was  
155 conducted for 30 min with a rabbit anti-mouse-LAMP1 antibody (BD Bioscience, USA). The  
156 goat anti rabbit Alexa Fluor 594 (BD Pharmingen, USA) secondary antibody was applied for  
157 30 min. The cells were washed three times in PBS and mounted using Dako mounting medium  
158 (DakoCytomation, Australia). Confocal microscopy was performed using spinning disk and z-  
159 stacks were taken in slices of 1  $\mu\text{m}$ .

**160 Griess assay**

161 The content of NO in the cell culture media was determined by Griess assay as described  
162 previously (Wilhelm et al., 2001). 50  $\mu\text{l}$  cell culture medium was mixed with equal volumes of  
163 Griess reagents (1% sulphanilamide in 2.5%  $\text{H}_3\text{PO}_4$ , Sigma, USA), then 50  $\mu\text{l}$  Griess reagent  
164 (0.1% naphthylenediamide dihydrochloride, Sigma, USA) was added and incubated at room  
165 temperature for 10 min. The absorbance at 540 nm was measured by a microplate reader (Bio-  
166 Rad, USA) and compared to a standard nitrite curve using sodium nitrite (Sigma, USA).

**167 Statistical analysis**

168 Flow cytometry was conducted at least three times in duplicate or triplicate wells. Statistical  
169 significance was determined by Student's unpaired t-test. P values of less than 0.05 were  
170 considered statistically significant.

171





**173 Results****174 DFTD cells can be phagocytosed by macrophages from B6.WT and B6.TNF<sup>-/-</sup> mice.**

175 To determine if DFTD cells could be phagocytosed, BMDMs from B6.WT and B6.TNF<sup>-/-</sup> mice  
176 (CTV labelled; blue) were co-incubated with DFTD C5065 cells (CFSE-labelled; green). After  
177 4 hours and 24 hours culture, phagocytosis was analysed by confocal microscopy (Figure 1).  
178 Green DFTD cells could be identified within the blue macrophages from both B6.WT and  
179 B6.TNF<sup>-/-</sup> mice. When z-stacks were analysed the green fragments were identified inside the  
180 macrophages, suggesting the tumour cells had been engulfed (Fig 1). The degradation of  
181 phagocytosed cellular material involves the process of phagosome maturation through  
182 homotypic and heterotypic fusion of early endosomes, late endosomes and lysosomes (Zhou  
183 and Yu, 2008). The presence of lysosomal-associated membrane protein 1 (LAMP1) was used  
184 to discriminate a late phase of phagocytosis, after phagosomes/lysosome fusion (Tjelle et al.,  
185 2000). As BMDMs from B6.WT and B6.TNF<sup>-/-</sup> mice can phagocytose DFTD cells, it suggests  
186 that TNF is not essential for phagocytosis and that DFTD cells are not resistant to phagocytosis.

187

**188 TNF deficiency results in enhanced phagocytic capacity in IFN $\gamma$ /LPS treated  
189 macrophages.**

190 Confocal microscopy showed that DFTD cells are phagocytosed by BMDMs from B6.WT and  
191 B6.TNF<sup>-/-</sup> mice, but flow cytometry was used to determine phagocytic efficiency. BMDMs  
192 were labelled with CTV and DFTD cells were labelled with CFSE, then incubated at ratios of  
193 E:T (10:1 and 5:1) at 37 °C or 4 °C for 4 hours. The phagocytosed DFTD cells were recognized  
194 as CFSE and CTV double positive cells. In the absence of stimulation (control) the phagocytic  
195 efficiencies of BMDMs from B6.WT and B6.TNF<sup>-/-</sup> mice were similar at both 10:1 (Fig 2A,

196 Suppl. Figure 1) and 5:1 (Fig 2B, Suppl. Figure 1) ratios. It suggests that TNF is not required  
197 for macrophage phagocytosis of DFTD cells under steady-state conditions.

198 In order to determine TNF involvement in phagocytosis following macrophage activation,  
199 BMDMs were stimulated with IFN $\gamma$  and LPS, IFN $\gamma$  alone, LPS alone or IL-4 alone. Following  
200 IFN $\gamma$ /LPS activation, macrophages from B6.TNF<sup>-/-</sup> mice displayed enhanced phagocytosis  
201 efficiency at both 10:1 (Fig 2A, Suppl. Figure 1) and 5:1 (Fig 2B, Suppl. Figure 1) ratios,  
202 compared with macrophages from B6.WT mice. However, BMDM macrophages from  
203 B6.TNF<sup>-/-</sup> mice stimulated with IFN $\gamma$  or IL-4 did not show a significant difference in phagocytic  
204 efficiency, compared with BMDM from B6.WT mice (Fig 2A, 2B, Suppl. Figure 1). Compared  
205 to untreated BMDMs, LPS treatment enhanced the phagocytic efficiency of BMDMs from  
206 wild-type and B6.TNF<sup>-/-</sup> mice (Fig 2A, 2B, Suppl. Figure 1). But no significant difference was  
207 shown between BMDMs from wild-type and B6.TNF<sup>-/-</sup> mice groups following LPS activation.

208 To confirm that the CFSE and CTV double positive cells represented phagocytosis rather than  
209 cell binding, DFTD cells and macrophages were co-incubated at 4 °C for 4 hours (Fig 2C, 2D,  
210 Suppl. Figure 1). The proportion of double positive cells was substantially reduced providing  
211 support for phagocytosis at 37 °C rather than just binding to the cell surface.

212

213 **IFN $\gamma$ /LPS, LPS activated BMDM from B6.TNF<sup>-/-</sup> mice phagocytose DFTD cells more**  
214 **effectively than BMDM from B6.WT mice following 24 hours incubation.**

215 The phagocytosis and subsequent disappearance of DFTD cells was analysed with flow  
216 cytometry after 24 hours incubation by enumerating the viable DFTD cells remaining. The  
217 absolute number of free DFTD cells was calculated using cell count beads. IFN $\gamma$ /LPS and LPS  
218 alone activated BMDMs from B6.TNF<sup>-/-</sup> mice cultured with DFTD cells for 24 hours resulted  
219 in fewer DFTD cells remaining compared to BMDMs from B6.WT mice at 10:1 and 5:1 ratios

220 (Fig 3A, 3B, Suppl. Figure 2). However, IFN $\gamma$  or IL-4 activated BMDMs from B6.TNF $^{-/-}$  mice  
221 had similar number of DFTD cells with wild-type controls at 10:1 and 5:1 ratios (Fig 3A, 3B,  
222 Suppl. Figure 2). These results indicated that LPS and potentially IFN $\gamma$ /LPS activated  
223 macrophages from B6.TNF $^{-/-}$  mice phagocytosed more DFTD cells than macrophages from the  
224 B6.WT mice. Thus, although phagocytosis by activated BMDMs was observed in the presence  
225 of TNF, the absence of TNF appeared to increase the phagocytic activity.

226

227 **The production of NO is diminished from IFN $\gamma$ /LPS or LPS activated B6.TNF $^{-/-}$**   
228 **macrophages after incubation with DFTD cells for 24 hours.**

229 The effector molecule NO is an essential macrophage product and is cytotoxic to tumour cells  
230 (MacMicking et al., 1997). As TNF regulates the production of NO in macrophages (Ding et  
231 al., 1988), we determined whether NO is related to TNF regulation of macrophage  
232 phagocytosis of DFTD cells. IFN $\gamma$ /LPS, IFN $\gamma$  or LPS treated macrophages from B6.WT,  
233 B6.TNF $^{-/-}$  mice were co-incubated with DFTD cells for 24 hours and the NO contents in the  
234 cell culture supernatant were measured. As shown in Fig 4, untreated macrophages from both  
235 mouse genotypes did not produce any detectable NO. In response to IFN $\gamma$ /LPS activation,  
236 BMDMs from B6.TNF $^{-/-}$  mice produced less NO than wild type controls. This was evident at  
237 10:1 (Fig 4A) and 5:1 (Fig 4B) ratios. Similarly, less NO was released from LPS activated  
238 BMDMs from B6.TNF $^{-/-}$  mice than wild type controls (Fig 4A, 4B). The IFN $\gamma$  treatment did  
239 not alter NO production of B6.WT, B6.TNF $^{-/-}$  macrophages after incubation with DFTD cells  
240 for 24 hours (Fig 4A, 4B). The production of NO might associate with the alteration of  
241 phagocytosis in IFN $\gamma$ /LPS and LPS alone treated B6.TNF $^{-/-}$  macrophages.

242

243 **TNF-associated alteration of macrophage phagocytosis during treatment with IFN $\gamma$ /LPS**  
244 **seems independent of NO production.**

245 To determine the association of NO with increased phagocytic activity in IFN $\gamma$ /LPS treated  
246 B6.TNF<sup>-/-</sup> macrophages. NO production was blocked by the inhibitor of NO synthesis, L-N6-  
247 (1-Iminoethyl) lysine dihydrochlorideinducible (L-NIL). After the incubation with IFN $\gamma$ /LPS  
248 or IFN $\gamma$ /LPS and L-NIL for 24 hours, BMDMs from B6.WT and B6.TNF<sup>-/-</sup> mice were co-  
249 incubated with DFTD cells for 24 hours. The number of DFTD cells was measured by flow  
250 cytometry and cell counting beads. As shown in Fig 5, L-NIL did not alter phagocytosis  
251 following stimulation with IFN $\gamma$ /LPS of macrophages from B6.WT or B6. TNF<sup>-/-</sup> mice. In  
252 addition, compared to IFN $\gamma$ /LPS treatment, L-NIL treatment did not alter the phagocytic ability  
253 of macrophages from B6.WT or B6.TNF<sup>-/-</sup> mice (Fig 5). Thus, it suggests that NO was  
254 unrelated to the altered phagocytic ability of IFN $\gamma$ /LPS treated macrophages from B6.TNF<sup>-/-</sup>  
255 mice.

256

## 257 Discussion

258 Our study shows that DFTD cells are phagocytosed effectively by murine BMDMs and that  
259 TNF modulates this ability. While we acknowledge the limitations imposed on far reaching  
260 conclusions by the experimental combination of mouse macrophage and devil tumor cells the  
261 main consequences of our findings are that an avoidance of phagocytosis by DFTD cells is  
262 unlikely to contribute to immune escape and that TNF is not necessary for phagocytosis, but  
263 negatively regulates phagocytosis by activated macrophages. **Antibody-dependent  
264 phagocytosis was not explored in this project because cross-species effects are unknown.**

265 The absence of MHC-I expression on DFT1 cells prevents the activation of CD8<sup>+</sup> T cells and  
266 thus interferes with the adaptive cellular immune response (Siddle et al., 2013). Nevertheless,  
267 devils immunised with DFTD antigens (Kreiss et al., 2015; Tovar et al., 2017) and some  
268 DFTD-inoculated devils (Pye et al., 2016a) can produce DFTD-specific antibodies which is in  
269 line with antibody mediated opsonisation of DFT1 cells and subsequent phagocytosis of tumor  
270 cells by macrophages. However, tumour cells can avoid phagocytosis by expressing inhibitory  
271 molecules such as CD47 which is part of the immune checkpoint inhibitory pathway (Alvey  
272 and Discher, 2017), and CD47 has been identified in transcriptome analysis from devil  
273 mononuclear cells (Flies et al., 2017). Hence, there is the potential for DFT1 cells to express  
274 this molecule. In the absence of monoclonal antibodies to identify inhibitory molecules and in  
275 particular CD47, we conducted phagocytosis experiments of DFT1 cells by flow cytometry  
276 and confocal microscopy using bone marrow-derived mouse macrophages in a proof of  
277 principle approach. **We could show that DFT1 cells can be phagocytosed supporting the notion  
278 that antibody-opsonised DFT1 cells could also be sensitive to phagocytosis *in vivo* in the  
279 Tasmanian devil after immunization** (Kreiss et al., 2015; Pye et al., 2016a; Tovar et al., 2017).  
280 After determining that mouse macrophages effectively phagocytose DFT1 tumour cells we  
281 then investigated whether TNF was required. In the absence of stimulation, the presence of

282 TNF made no difference to the phagocytic efficiency. But following activation with IFN $\gamma$ /LPS  
283 or LPS (but not IFN $\gamma$ ), the presence of TNF reduced phagocytic activity. Although TNF is  
284 regarded as a master regulator of inflammatory cytokine production (Parameswaran and Patial,  
285 2010) there are reports that TNF can inhibit macrophage phagocytic activity. Exogenous TNF  
286 has been shown to reduce the macrophage capacity to ingest apoptotic cells (McPhillips et al.,  
287 2007). This inhibition appears specific for apoptotic cells as it is not seen with beads or  
288 antibody-opsonized cells (McPhillips et al., 2007). The authors propose that within the  
289 inflammatory environment, the reduced phagocytic ability may 'contribute to the local  
290 intensity of the inflammatory response'. Macrophages stimulated with LPS produce TNF and  
291 this would inhibit macrophage phagocytosis of apoptotic cells in an autocrine manner (Feng et  
292 al., 2011). TNF is also produced by IFN $\gamma$ /LPS activated macrophages (Cohen et al., 2015; Patel  
293 et al., 2012). IFN $\gamma$  on its own is unable to activate macrophages to produce TNF, but can do so  
294 in the presence of LPS (Gifford and Lohmann-Matthes, 1987). This observation is  
295 controversial as some studies have shown that IFN $\gamma$  primed macrophages (Fernandez-  
296 Boyanapalli et al., 2010; Vila-del Sol et al., 2008) can produce TNF. Furthermore, IFN $\gamma$   
297 appears to restore an impaired ability of macrophages to phagocytose apoptotic cells in a nitric  
298 oxide-dependent manner that requires TNF production (Fernandez-Boyanapalli et al., 2010;  
299 Vila-del Sol et al., 2008). This might be due to the macrophages coming from different sources  
300 and at different stages of maturation. A further caveat is the potential presence of traces of  
301 contaminating TLR ligands. Already minute amounts can interfere with the activation of  
302 macrophages. Finally, while TNF has no effect on phagocytosis by immature macrophages, it  
303 can reduce phagocytosis by mature macrophages (McPhillips et al., 2007).

304 Phagocytosis of pathogens by macrophages requires NO and TNF dependent NO production  
305 is required for the enhanced phagocytosis of apoptotic cells by IFN $\gamma$  activated macrophages  
306 (Fernandez-Boyanapalli et al., 2010). However, NO can impair phagocytosis of fluorescent

307 particles by affecting cytoskeletal assembly and pseudopod formation (Jun et al., 1996). TNF  
308 is definitely involved in NO production as it induces iNOS expression via the NF- $\kappa$ B signaling  
309 pathway (Ding et al., 1988; Patel et al., 2012). Furthermore, the expression of iNOS  
310 downstream of IFN $\gamma$ /LPS activation of macrophages requires TNF (Chan and Riches, 2001).  
311 TNF dependent NO production is required for the enhanced phagocytosis of apoptotic cells by  
312 IFN $\gamma$  activated macrophages (Fernandez-Boyanapalli et al., 2010). We blocked production of  
313 NO by using L-NIL, but inhibition of NO production did not alter phagocytosis efficiency in  
314 IFN $\gamma$ /LPS treated macrophages. It suggests that NO is independent of TNF presence in  
315 IFN $\gamma$ /LPS treated macrophages. Moreover, actin polymerization is an essential event in the  
316 process of macrophage phagocytosis. It has been suggested that exogenous TNF decreases  
317 actin reorganization in J774 macrophages (Peppelenbosch et al., 1999). The involvement of  
318 actin and TNF inhibition of phagocytosis activity in IFN $\gamma$ /LPS activated macrophages needs  
319 to be further investigated. Finally, recent observations point to a new role for TNF in the  
320 maintenance of a M1 phenotype in macrophages (Kratochvill et al., 2015; Schleicher et al.,  
321 2016). Since we used TNF-negative macrophages in our experiments we cannot exclude the  
322 possibility that a part of the cell population has differentiated to M2 macrophages with  
323 consequences for their ability to produce pro-inflammatory mediators and phagocytose tumor  
324 cells. This aspect has to be explored in further detailed studies.

325

326

327

328

329



330 **Acknowledgements**

331 We thank Terry Pinfold for assistance using flow cytometry, and Peta Lawrie and Paul Scanon  
332 for animal husbandry. We also thank Yilan Zhen for advice on the performance of confocal  
333 microscopy. XL was supported by a AMU/UTAS postgraduate scholarship and research funds  
334 were provided by grants from the Australian Research Council (DP130100715, LP130100218)  
335 and the Dr Eric Guiler Tasmanian devil research grants administered through the University of  
336 Tasmania Foundation. Part of the data in this manuscript have been presented as poster at the  
337 ICI Melbourne in 2016 and have been published in the conference proceedings: Li X., Lyons  
338 A. B., **Körner H.** & G. Woods. (2016) Murine macrophage phagocytosis of devil facial tumour  
339 disease cells. European Journal of Immunology 46, 439 (supplement) Meeting Abstract 422.  
340 (published abstract).

341

342

343 **Conflict of interest**

344 The authors state that they had no conflict of interest.

345

346 **Figures legends**

347 **Figure 1. Confocal microscope analysis of macrophage phagocytosing DFTD cells.** Co-  
348 incubate CTV labelled BMDMs with CFSE labelled DFTD cells for 4 hours and 24 hours, cells  
349 were fixed and permeabilized, then labelled with anti-LAMP1 antibody. Phagocytosis was  
350 analysed in confocal microscopy. The z-stack (white arrow) demonstrated that tumour cells are  
351 located inside B6.WT and B6.TNF<sup>-/-</sup> macrophages after 4 hours and 24 hours incubation (Green,  
352 DFTD cells; Blue, macrophages; Red, LAMP1).

353

354 **Figure 2. IFN $\gamma$ /LPS treated B6.TNF<sup>-/-</sup> BMDMs exhibited enhanced phagocytic efficiency**  
355 **of DFTD cells compared to B6.WT BMDMs.** B6.WT and B6.TNF<sup>-/-</sup> BMDMs were treated  
356 with IFN $\gamma$ /LPS, IFN $\gamma$  alone, LPS alone, or IL-4 alone. BMDMs were labelled with CTV and  
357 DFTD cells were labelled with CFSE. After labelling, BMDMs were co-incubated with DFTD  
358 cells for 4 hours. The percentage of phagocytosed DFTD cells in the incubation of 37 °C (A,  
359 B) and 4 °C (C, D) was investigated by flow cytometry. The ratio of BMDMs: DFTD cells  
360 indicates effector: target (E:T). Data were from a total of 3-7 mice within two or three  
361 independent experiments (biological replicates),  $\Delta$  p < 0.05 versus WT control, # p < 0.05  
362 versus B6.TNF<sup>-/-</sup> control, \* p < 0.05 versus WT versus B6.TNF<sup>-/-</sup>, NS not significant.

363

364 **Figure 3: IFN $\gamma$ /LPS, LPS activated B6.TNF<sup>-/-</sup> BMDMs are more effective at removing**  
365 **DFTD cells than B6.WT BMDMs after 24 hours incubation.** BMDMs from B6.WT and  
366 B6.TNF<sup>-/-</sup> mice were treated with IFN $\gamma$ /LPS, IFN $\gamma$  alone, LPS alone, or IL-4 alone. BMDMs  
367 were labelled with CTV and DFTD cells were labelled with CFSE. After labelling, BMDMs  
368 were incubated with DFTD cells for 24 hours, and the absolute number of viable DFTD cells  
369 was calculated using flow cytometry with cell count beads. The ratio of BMDMs: DFTD cells  
370 indicates effector: target (E:T). Data were from a total of 3-7 mice within two or three  
371 independent experiments (biological replicates), \* p < 0.05.

372

373 **Figure 4. Reduced NO production from IFN $\gamma$ /LPS, LPS activated B6.TNF<sup>-/-</sup> macrophages**  
374 **phagocytosis of DFTD cells.** B6.WT and B6.TNF<sup>-/-</sup> macrophages were stimulated with  
375 IFN $\gamma$ /LPS, IFN $\gamma$  or LPS overnight. Macrophages were co-incubated with DFTD cells at 10:1(A)  
376 and 5:1 (B) ratios, the concentration of NO in the cell culture supernatant was analysed in

377 Griess assay. The ratio of BMDMs: DFTD cells indicates effector: target (E:T). Data were from  
378 3 mice (biological replicates),  $\Delta\Delta p < 0.01$  versus WT control,  $## p < 0.01$  versus B6.TNF<sup>-/-</sup>  
379 control, \*  $p < 0.05$  versus WT versus B6.TNF<sup>-/-</sup>.

380

381 **Figure 5. NO is unrelated to the TNF involved macrophage phagocytosis of DFTD cells.**

382 B6.WT and B6.TNF<sup>-/-</sup> BMDMs were treated with IFN $\gamma$ /LPS or IFN $\gamma$ /LPS with L-NIL  
383 overnight. After incubation with BMDMs and DFTD cells for 24 hours, the numbers of DFTD  
384 cells at E:T 10:1 (A), 5:1 (B) ratios were analysed by flow cytometry and cell counting beads.  
385 The ratio of BMDMs: DFTD cells indicates effector: target (E:T). The numbers of DFTD cells  
386 were calculated as methods described. Data were from a total of 3-5 mice within two or three  
387 independent experiments (biological replicates), \*  $p < 0.05$ , NS not significant.

388

389 **References:**

- 390 Aderem, A., and Underhill, D.M. (1999). Mechanisms of phagocytosis in macrophages. *Annu*  
391 *Rev Immunol* *17*, 593-623.
- 392 Alvey, C., and Discher, D.E. (2017). Engineering macrophages to eat cancer: from "marker of  
393 self" CD47 and phagocytosis to differentiation. *J Leukoc Biol* *102*, 31-40.
- 394 Borges, V.M., Vandivier, R.W., McPhillips, K.A., Kench, J.A., Morimoto, K., Groshong, S.D.,  
395 Richens, T.R., Graham, B.B., Muldrow, A.M., Van Heule, L., *et al.* (2009). TNFalpha inhibits  
396 apoptotic cell clearance in the lung, exacerbating acute inflammation. *Am J Physiol Lung Cell*  
397 *Mol Physiol* *297*, L586-595.
- 398 Chan, E.D., and Riches, D.W. (2001). IFN-gamma + LPS induction of iNOS is modulated by  
399 ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. *Am J Physiol Cell Physiol*  
400 *280*, C441-450.
- 401 Cohen, H.B., Ward, A., Hamidzadeh, K., Ravid, K., and Mosser, D.M. (2015). IFN-gamma  
402 Prevents Adenosine Receptor (A2bR) Upregulation To Sustain the Macrophage Activation  
403 Response. *J Immunol* *195*, 3828-3837.
- 404 Ding, A.H., Nathan, C.F., and Stuehr, D.J. (1988). Release of reactive nitrogen intermediates  
405 and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of  
406 activating cytokines and evidence for independent production. *J Immunol* *141*, 2407-2412.
- 407 Feng, X., Deng, T., Zhang, Y., Su, S., Wei, C., and Han, D. (2011). Lipopolysaccharide inhibits  
408 macrophage phagocytosis of apoptotic neutrophils by regulating the production of tumour  
409 necrosis factor alpha and growth arrest-specific gene 6. *Immunology* *132*, 287-295.
- 410 Fernandez-Boyanapalli, R., McPhillips, K.A., Frasca, S.C., Janssen, W.J., Dinauer, M.C.,  
411 Riches, D.W., Henson, P.M., Byrne, A., and Bratton, D.L. (2010). Impaired phagocytosis of  
412 apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-gamma  
413 in a nitric oxide-dependent manner. *J Immunol* *185*, 4030-4041.
- 414 Flies, A.S., Blackburn, N.B., Lyons, A.B., Hayball, J.D., and Woods, G.M. (2017).  
415 Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the  
416 Transmissible Tasmanian Devil Facial Tumor Disease. *Front Immunol* *8*, 513.
- 417 Gifford, G.E., and Lohmann-Matthes, M.L. (1987). Gamma interferon priming of mouse and  
418 human macrophages for induction of tumor necrosis factor production by bacterial  
419 lipopolysaccharide. *J Natl Cancer Inst* *78*, 121-124.
- 420 Gordon, S., and Martinez, F.O. (2010). Alternative activation of macrophages: mechanism and  
421 functions. *Immunity* *32*, 593-604.
- 422 Hu, S., Wei, W., and Korner, H. (2017). The role of monocytes in models of infection by  
423 protozoan parasites. *Molecular immunology* *88*, 174-184.
- 424 Jones, M.E., Cockburn, A., Hamede, R., Hawkins, C., Hesterman, H., Lachish, S., Mann, D.,  
425 McCallum, H., and Pemberton, D. (2008). Life-history change in disease-ravaged Tasmanian  
426 devil populations. *Proceedings of the National Academy of Sciences of the United States of*  
427 *America* *105*, 10023-10027.
- 428 Jun, C.D., Han, M.K., Kim, U.H., and Chung, H.T. (1996). Nitric oxide induces ADP-  
429 ribosylation of actin in murine macrophages: association with the inhibition of pseudopodia  
430 formation, phagocytic activity, and adherence on a laminin substratum. *Cellular immunology*  
431 *174*, 25-34.
- 432 Körner, H., Cook, M., Riminton, D.S., Lemckert, F.A., Hoek, R.M., Ledermann, B., Köntgen,  
433 F., Fazekas de St Groth, B., and Sedgwick, J.D. (1997). Distinct roles for lymphotoxin-alpha  
434 and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. *Eur. J.*  
435 *Immunol.* *27*, 2600-2609.

- 436 Kratochvill, F., Neale, G., Haverkamp, J.M., Van de Velde, L.A., Smith, A.M., Kawauchi, D.,  
437 McEvoy, J., Roussel, M.F., Dyer, M.A., Qualls, J.E., and Murray, P.J. (2015). TNF  
438 Counterbalances the Emergence of M2 Tumor Macrophages. *Cell Rep* 12, 1902-1914.
- 439 Kreiss, A., Brown, G.K., Tovar, C., Lyons, A.B., and Woods, G.M. (2015). Evidence for  
440 induction of humoral and cytotoxic immune responses against devil facial tumor disease cells  
441 in Tasmanian devils (*Sarcophilus harrisii*) immunized with killed cell preparations. *Vaccine* 33,  
442 3016-3025.
- 443 Kreiss, A., Obendorf, D.L., Hemsley, S., Canfield, P.J., and Woods, G.M. (2009). A  
444 histological and immunohistochemical analysis of lymphoid tissues of the Tasmanian devil.  
445 *Anat Rec (Hoboken)* 292, 611-620.
- 446 Leichtle, A., Hernandez, M., Ebmeyer, J., Yamasaki, K., Lai, Y., Radek, K., Choung, Y.H.,  
447 Euteneuer, S., Pak, K., Gallo, R., *et al.* (2010). CC chemokine ligand 3 overcomes the  
448 bacteriocidal and phagocytic defect of macrophages and hastens recovery from experimental  
449 otitis media in TNF<sup>-/-</sup> mice. *J Immunol* 184, 3087-3097.
- 450 MacMicking, J., Xie, Q.W., and Nathan, C. (1997). Nitric oxide and macrophage function.  
451 *Annu Rev Immunol* 15, 323-350.
- 452 Mannel, D.N., Moore, R.N., and Mergenhagen, S.E. (1980). Macrophages as a source of  
453 tumoricidal activity (tumor-necrotizing factor). *Infect. Immun.* 30, 523-530.
- 454 McPhillips, K., Janssen, W.J., Ghosh, M., Byrne, A., Gardai, S., Remigio, L., Bratton, D.L.,  
455 Kang, J.L., and Henson, P. (2007). TNF-alpha inhibits macrophage clearance of apoptotic cells  
456 via cytosolic phospholipase A2 and oxidant-dependent mechanisms. *J Immunol* 178, 8117-  
457 8126.
- 458 Murray, P.J., Allen, J.E., Biswas, S.K., Fisher, E.A., Gilroy, D.W., Goerdt, S., Gordon, S.,  
459 Hamilton, J.A., Ivashkiv, L.B., Lawrence, T., *et al.* (2014). Macrophage activation and  
460 polarization: nomenclature and experimental guidelines. *Immunity* 41, 14-20.
- 461 Parameswaran, N., and Patial, S. (2010). Tumor necrosis factor-alpha signaling in macrophages.  
462 *Crit Rev Eukaryot Gene Expr* 20, 87-103.
- 463 Patel, N.R., Bole, M., Chen, C., Hardin, C.C., Kho, A.T., Mih, J., Deng, L., Butler, J.,  
464 Tschumperlin, D., Fredberg, J.J., *et al.* (2012). Cell elasticity determines macrophage function.  
465 *PLoS ONE* 7, e41024.
- 466 Pearse, A.M., Swift, K., Hodson, P., Hua, B., McCallum, H., Pyecroft, S., Taylor, R., Eldridge,  
467 M.D., and Belov, K. (2012). Evolution in a transmissible cancer: a study of the chromosomal  
468 changes in devil facial tumor (DFT) as it spreads through the wild Tasmanian devil population.  
469 *Cancer Genet* 205, 101-112.
- 470 Peppelenbosch, M., Boone, E., Jones, G.E., van Deventer, S.J., Haegeman, G., Fiers, W.,  
471 Grooten, J., and Ridley, A.J. (1999). Multiple signal transduction pathways regulate TNF-  
472 induced actin reorganization in macrophages: inhibition of Cdc42-mediated filopodium  
473 formation by TNF. *J Immunol* 162, 837-845.
- 474 Pye, R., Hamede, R., Siddle, H.V., Caldwell, A., Knowles, G.W., Swift, K., Kreiss, A., Jones,  
475 M.E., Lyons, A.B., and Woods, G.M. (2016a). Demonstration of immune responses against  
476 devil facial tumour disease in wild Tasmanian devils. *Biol Lett* 12.
- 477 Pye, R.J., Pemberton, D., Tovar, C., Tubio, J.M., Dun, K.A., Fox, S., Darby, J., Hayes, D.,  
478 Knowles, G.W., Kreiss, A., *et al.* (2016b). A second transmissible cancer in Tasmanian devils.  
479 *Proceedings of the National Academy of Sciences of the United States of America* 113, 374-  
480 379.
- 481 Schleicher, U., and Bogdan, C. (2009). Generation, culture and flow-cytometric  
482 characterization of primary mouse macrophages. *Methods Mol. Biol.* 531, 203-224.
- 483 Schleicher, U., Paduch, K., Debus, A., Obermeyer, S., Konig, T., Kling, J.C., Ribechini, E.,  
484 Dudziak, D., Mougiakakos, D., Murray, P.J., *et al.* (2016). TNF-Mediated Restriction of

- 485 Arginase 1 Expression in Myeloid Cells Triggers Type 2 NO Synthase Activity at the Site of  
486 Infection. *Cell Rep* 15, 1062-1075.
- 487 Sedgwick, J.D., Riminton, D.S., Cyster, J.G., and Körner, H. (2000). Tumor necrosis factor: a  
488 master-regulator of leukocyte movement. *Immunol Today* 21, 110-113.
- 489 Siddle, H.V., Kreiss, A., Tovar, C., Yuen, C.K., Cheng, Y., Belov, K., Swift, K., Pearse, A.M.,  
490 Hamede, R., Jones, M.E., *et al.* (2013). Reversible epigenetic down-regulation of MHC  
491 molecules by devil facial tumour disease illustrates immune escape by a contagious cancer.  
492 *Proceedings of the National Academy of Sciences of the United States of America* 110, 5103-  
493 5108.
- 494 Tauber, A.I. (2003). Metchnikoff and the phagocytosis theory. *Nat Rev Mol Cell Biol* 4, 897-  
495 901.
- 496 Taylor, P.R., Martinez-Pomares, L., Stacey, M., Lin, H.H., Brown, G.D., and Gordon, S. (2005).  
497 Macrophage receptors and immune recognition. *Annu Rev Immunol* 23, 901-944.
- 498 Tjelle, T.E., Lovdal, T., and Berg, T. (2000). Phagosome dynamics and function. *Bioessays* 22,  
499 255-263.
- 500 Tovar, C., Pye, R.J., Kreiss, A., Cheng, Y., Brown, G.K., Darby, J., Malley, R.C., Siddle, H.V.,  
501 Skjodt, K., Kaufman, J., *et al.* (2017). Regression of devil facial tumour disease following  
502 immunotherapy in immunised Tasmanian devils. *Sci Rep* 7, 43827.
- 503 Underhill, D.M., and Ozinsky, A. (2002). Phagocytosis of microbes: complexity in action.  
504 *Annu Rev Immunol* 20, 825-852.
- 505 Varin, A., Mukhopadhyay, S., Herbein, G., and Gordon, S. (2010). Alternative activation of  
506 macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced  
507 signalling and cytokine secretion. *Blood* 115, 353-362.
- 508 Vila-del Sol, V., Punzon, C., and Fresno, M. (2008). IFN-gamma-induced TNF-alpha  
509 expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages. *J*  
510 *Immunol* 181, 4461-4470.
- 511 Wilhelm, P., Ritter, U., Labbow, S., Donhauser, N., Röllinghoff, M., Bogdan, C., and Körner,  
512 H. (2001). Rapidly Fatal Leishmaniasis in Resistant C57BL/6 Mice Lacking TNF. *J. Immunol.*  
513 *166*, 4012-4019.
- 514 Zhou, Z., and Yu, X. (2008). Phagosome maturation during the removal of apoptotic cells:  
515 receptors lead the way. *Trends in cell biology* 18, 474-485.
- 516